Skip to main content

Expand the frontiers in regenerative medicine with the power and flexibility of stem cells. This emerging therapeutic field promises the ability to correct hereditary defects and to rebuild vital tissue functions lost to degenerative diseases or injury. At Bio-Techne, we apply our years of stem cell expertise to supporting regenerative medicine manufacturing. We will partner with you as you produce revolutionary and scalable cell replacement therapies.

Click on the stem cell types below to learn how we can support your Regenerative Medicine Research.

    Gowned up worker in cleanroom
    ES iPSC - Embryonic and Induced Pluripotent Stem Cell Embryonic Fibroblasts, Media, and Marker Panels

    Induced Pluripotent Stem Cells (iPSC)

    iPSCs are generated by reprogramming easily obtained somatic cells. Allogeneic iPSC therapies offer the promise of generating universal cell banks to treat multiple patients with less cost and more rapid development.


    mesenchymal stem cells (MSC) in culture at Bio-Techne

    Mesenchymal Stem Cells (MSC)

    Multipotent MSC can be exploited for their ability to suppress the immune system, particularly in graft vs. host disease and chronic inflammation such as COVID-19.

    NSC Neuron Stem Cells Identification and Expansion Kits

    Neural Stem Cells (NSC)

    NSC-based cell therapies address neurodegenerative diseases as well as brain and spinal cord injuries. These multipotent cells can differentiate into all types of neurons, astroglia, and oligodendrocytes.

    HSC Hematopoietic Stem Cell Supplements, Media, and Reagents

    Hematopoietic Stem Cells (HSC)

    Genetically engineered HSC are valuable in bone marrow transplantation for targeting blood cancers and autoimmune diseases and treating inherited genetic defects.

    What Is Regenerative Medicine?

    Regenerative medicine is a groundbreaking approach for the treatment of debilitating degenerative diseases, tissue injury, and pathogenic genetic defects. In regenerative medicine, stem cells are isolated from a patient, engineered and differentiated into a specific cell type, and given back to the patient. Mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and neural stem cells (NSC) can be differentiated into various cell types within their lineage. This offers the promise to generate specific terminally differentiated cells for the regeneration of most tissues in the body. Induced pluripotent stem cells (iPSC) are generated by the reprogramming of easily obtained somatic cells (e.g. fibroblasts or peripheral blood cells) into a pluripotent state with the ability to differentiate into any cell type.

    Autologous therapies are personalized medicines that involve modifying a patient’s cells before readministration, while allogeneic therapies rely on generating an off-the-shelf cell product that can be used for different patients. Allogeneic approaches offer lower cost and require less time before patient treatment but also hold greater risk of immune rejection. In addition, regulatory clearance would be streamlined because allogeneic treatments could be thoroughly tested as universal cell banks and avoid some of the individualized testing required for separate autologous treatments.

    Gene engineering, either by non-viral or virus-based methods, can introduce therapeutic proteins to tarteted cells and delete detrimental proteins. This can increase the therapeutic efficacy of the cells as well as increase their tissue engraftment and avoid host immune rejection. The production of regenerative medicine products and other advanced therapy medicinal products (ATMP) should take place in a certified facility with GMP-grade raw materials and analytical instruments validated for use in cleanroom settings.